2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2176

A Novel Composite Score Reflecting Disease Activity Predicts Future Knee Replacements: Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 2559

A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2417

A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2270

A Pilot Study of the Psychosocial Impact of Undifferentiated Connective Tissue Disease

Psychology/Social Science Poster – ARP

9:00AM-11:00AM: Abstract Number: 2408

A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis

RA – Treatments Poster III: Safety and Outcomes – ARP

9:00AM-11:00AM: Abstract Number: 2263

A Qualitative Study Evaluating Near-Patient Tools Including a Mobile Application for Earlier RA Referral; Potential to Reduce Chronic Disease Burden

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2512

A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2095

A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2579

A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2167

A Randomised Controlled Clinical Trial Comparing the Effectiveness of 6 and 12 Weeks of a Shoulder Specific Exercise Programme for Patients with Rotator Cuff Related Shoulder Pain

Orthopedics, Low Back Pain, & Rehabilitation Poster – ACR/ARP

9:00AM-11:00AM: Abstract Number: 2718

A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 1964

A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: L07

A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2622

A Single Center Retrospective Analysis of Efficacy and Safety Between Low-Dose versus High-Dose Rituximab as Remission Induction Therapy with ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2661

A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.